A carregar...

Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men

Non-alcoholic steatohepatitis (NASH) is the most rapidly growing liver disease that is nevertheless without approved pharmacological treatment. Despite great effort in developing novel NASH therapeutics, many have failed in clinical trials. This has raised questions on the adequacy of preclinical mo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: van den Hoek, Anita M., Verschuren, Lars, Caspers, Martien P. M., Worms, Nicole, Menke, Aswin L., Princen, Hans M. G.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930243/
https://ncbi.nlm.nih.gov/pubmed/33658534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-83974-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!